Search Results - "Warcel, Dana"

Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial by Popat, Rakesh, Warcel, Dana, O'Nions, Jenny, Cowley, Anna, Smith, Sasha, Tucker, William R, Yong, Kwee, Esposti, Simona Degli

Get full text

Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies by Burt, Richard, Warcel, Dana, Fielding, Adele K.

“…Blinatumomab (Blincyto, Amgen), a bi-specific antibody, is a first-in-class, targeted immunotherapy agent for treatment of B-cell malignancies with a novel…”
Get full text

Antibody-drug conjugates for multiple myeloma by McMillan, Annabel, Warcel, Dana, Popat, Rakesh

“…Antibody-drug conjugates (ADC) are a new class of treatment for multiple myeloma (MM) patients, delivering a potent cytotoxic agent directly to the myeloma…”
Get more information

Durability of Response and Characterisation of Corneal events with Extended follow-up after Belantamab Mafodotin monotherapy for patients with relapsed/refractory Multiple Myeloma by Popat, Rakesh, Warcel, Dana, O'Nions, Jenny, Cowley, Anna, Smith, Sasha, Yong, Kwee, Esposti, Simona Degli

Get full text

Symptomatic Erythrocytosis Due to Homozygosity for Hb Luton [HBA2: c.269A>T (or HBA1)] and α-Thalassemia: A Clinical Update by Oliveira, Amelia, Warcel, Dana, Huntley, Nancy, Eleftheriou, Perla, Porter, John B.

“…A female proband homozygous for both Hb Luton [α89(FG1)His→Leu (CAC>CTC), HBA2: c.269A>T (or HBA1)], a high oxygen affinity hemoglobin (Hb), and for α +…”
Get full text

Service improvement system to enhance the safety of patients admitted on long-term warfarin by Warcel, Dana, Johnson, Daniel, Shah, Neeraj, shreeve, Norman

“…Abstract It is common for hospital inpatients on warfarin to suffer from fluctuations in their INR (international normalised ratio). Raised INRs are…”
Get full text

A Phase II Trial of Sequential Treatment with Cytoreductive Therapy and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukaemia, High-Risk MDS and Other High Risk Myeoid Malignancies: An Interim Report by Tsitsikas, Dimitris A, Warcel-Sibony, Dana, Oakervee, Heather E., Agrawal, Samir G, Smith, Matthew, Taussig, David C, de Vos, Johannes, Stewart, Elaine, Nicholas, Hannah, Gribben, John G., Cavenagh, James D

“…Abstract 3480 Outcomes for patients with refractory or relapsed acute myeloid leukaemia (AML) are extremely poor and allogeneic haemopoietic stem cell…”
Get full text